51487-58-2

Basic information

• Product Name: 1,4-BIS(3,4-DIMETHOXYPHENYL)BUTANE
• Synonyms: 1,4-BIS(3,4-DIMETHOXYPHENYL)BUTANE
• CAS NO: 51487-58-2
• Molecular Formula: C₂₀H₂₆O₄
• Molecular Weight: 330.42
• Mol File: 51487-58-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-BIS(3,4-DIMETHOXYPHENYL)BUTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-BIS(3,4-DIMETHOXYPHENYL)BUTANE(51487-58-2)
• EPA Substance Registry System: 1,4-BIS(3,4-DIMETHOXYPHENYL)BUTANE(51487-58-2)

Safety Data

• Hazardous Substances Data: 51487-58-2(Hazardous Substances Data)

Upstream product

• 4650-71-9 SK 31597 
• 94757-25-2 1,4-bis-(3,4-dimethoxy-phenyl)-buta-1,3-diene 
• 4650-69-5 2,5-Bis-(3,4-dimethoxy-phenyl)-furan 
• 854872-38-1 1-(2-bromo-4,5-dimethoxy-phenyl)-4-(3,4-dimethoxy-phenyl)-butane 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 628-21-7 1,4-Diiodobutane 
• 2859-78-1 4-Bromoveratrole 
• 13575-74-1 4-(3,4-dimethoxyphenyl)butanoic acid 
• 56880-86-5 4-(3,4-dimethoxyphenyl)butan-1-ol 
• 52417-29-5 4-(3,4-dimethoxyphenyl)butanal 
• 79631-01-9 1,2-dimethoxy-4-<1-<(1,1-dimethylethyl)dimethylsilyloxy>ethenyl>benzene 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 

Downstream Products

• 101432-05-7 4,4’-(butane-1,4-diyl)bis(benzene-1,2-diol) 
• 1018685-49-8 1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane 

Relevant articles and documents

Dihedral-Angle-Controlled Crossover from Static Hole Delocalization to Dynamic Hopping in Biaryl Cation Radicals

In cases of coherent charge-transfer mechanism in biaryl compounds the rates follow a squared cosine trend with varying dihedral angle. Herein we demonstrate using a series of biaryl cation radicals with varying dihedral angles that the hole stabilization

TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.